ArticleFrontiers in drug safety and regulation2026
Colistin use and outcomes in Kuwait public hospitals.
Article in Frontiers in drug safety and regulation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In Kuwait, colistin use has increased owing to an increased incidence of multidrug resistant infections. However, the optimal dosing regimen and its effectiveness and safety are unclear. We aimed to describe colistin use in Kuwait and evaluate the associated clinical outcomes and safety profiles. Methods: This multicentre, retrospective, observational study used data collected from five hospitals. Study outcomes included cure rates, incidence of nephrotoxicity, and mortality. Logistic regression models were used to study the effect of colistin dosing patterns (loading dose, daily maintenance dose, and duration of therapy) on study outcomes. The models were adjusted for age, sex, and hospital unit (ICU/non-ICU), baseline creatinine clearance, being on dialysis, pathogen type, receiving concomitant antibiotics, and site of infection. Results: Of 205 patients treated with colistin, 117 were treated in intensive care units (ICUs) and 88 were treated in other units. Of the 205 patients, 145 (70.7%) achieved clinical cure. The cure rate was lower in ICU patients than in non-ICU patients. Fifty patients experienced nephrotoxicity; 47 died, and 11 experienced neurotoxicity. The incidence of nephrotoxicity did not differ significantly by hospital unit, whereas the case fatality rate was significantly higher and the incidence of neurotoxicity was significantly lower in ICU patients. Administration of a loading dose was not associated with the cure rate, incidence of nephrotoxicity, or case fatality rate. Higher maintenance doses were associated with higher cure rates, (odds ratio [OR], 2.77; 95% confidence interval [CI], 1.04-7.37) and lower fatality rates (OR, 0.29; 95% CI, 0.09-0.95), but more likely to develop nephrotoxicity (OR, 2.60; 95% CI, 1.08-6.23). Conclusion: Administration of high maintenance doses of colistin was associated with higher cure rates but was also associated with a higher incidence of nephrotoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.